Last updated on February 2018

Stage 1 Study of ARALAST NP and GLASSIA in A1PI


Brief description of study

The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ Chronic obstructive pulmonary disease (COPD).

Clinical Study Identifier: NCT02722304

Contact Investigators or Research Sites near you

Start Over

Marc Buggelsheim, PhD

Pulmonary Disease Specialists, P.A., / PDS Research
Kissimmee, FL United States
  Connect »

Marc Buggelsheim, PhD

L&C Professional Medical Research Institute
Miami, FL United States
  Connect »

Marc Buggelsheim, PhD

Hope Clinical Trials
Miami, FL United States
  Connect »

Marc Buggelsheim, PhD

Eminence Medical & Clinical Research
Tampa, FL United States
  Connect »

Marc Buggelsheim, PhD

Indiana University Health
Indianapolis, IN United States
  Connect »

Marc Buggelsheim, PhD

American Research
Jeffersonville, IN United States
  Connect »

Marc Buggelsheim, PhD

Advanced Research Institute
Sparks, NV United States
  Connect »

Marc Buggelsheim, PhD

Pulmonary Health Physicians
Syracuse, NY United States
  Connect »

Marc Buggelsheim, PhD

Clinical Research of Gastonia
Gastonia, NC United States
  Connect »

Marc Buggelsheim, PhD

Alpha Research Associates, LLC
Dayton, OH United States
  Connect »

Marc Buggelsheim, PhD

Katy Pulmonary Associates, PA
Houston, TX United States
  Connect »

Marc Buggelsheim, PhD

Element Research Group
San Antonio, TX United States
  Connect »